Dr. Daniel Cameron & Associates, located in the Hudson Valley New York area, is uniquely positioned in a region where Lyme disease is endemic, enabling the practice to participate in much-needed clinical research projects, including the validation of newly developed Lyme disease tests.
Since 1987, Dr. Cameron has been evaluating and treating thousands of individuals with tick-borne illnesses. He has served as a clinical investigator for numerous clinical trials and has participated in national and international conferences.
Having a significant number of study participants is important when conducting randomized, double-blind clinical trials, says Dr. Cameron. The National Institute of Health (NIH) has conducted four trials over the past decade. In total, those studies included a mere 200 Lyme disease patients.
“Run the numbers. With 300,000 people diagnosed with Lyme disease each year, the NIH, over the past decade, has only studied 200 patients. Treatment decisions are being made based on clinical trials that involve a minuscule number of subjects.” The IDSA treatment guidelines, which dictate the treatment of hundreds of thousands of patients, are based on the results of those four NIH trials, which included a total of 200 patients, he adds.
Dr. Cameron is currently involved in a project to validate the effectiveness of a newly developed Lyme disease test. It is not a treatment study, he points out. But volunteers are still needed.
“The more volunteers with newly diagnosed Lyme disease, the more we can help to find a new test,” says Dr. Daniel Cameron, director of the tick-borne validation program. “Because of the increase in Lyme disease cases, we have had a strong summer with volunteers enrolling but we could still use more participants.”
Dr. Daniel Cameron & Associates welcomes volunteers, who are newly diagnosed with Lyme disease, as well as those who have never had the disease.
If interested in participating in the study, please call 914-666-4665.
NOTE FROM DR. CAMERON: THE STUDY IS CURRENTLY OVER, THANKS FOR YOUR INTEREST.
Leave a Reply